SCHEDULE

Day 2: Therapeutics, Investment, and Strategic Collaboration

Tuesday, November 10, 2026

7:30–8:30 AM

Registration and Breakfast

8:30–8:45 AM

OPENING
Welcome and Day 2 Overview

David Scheer, President, Scheer & Company

Eric Winer, Director, Yale Cancer Center; President and Physician-in-Chief, Smilow Cancer Hospital

Jodie Gillon, President and Chief Executive Officer, BioCT

8:45–8:55 AM

OPENING KEYNOTE
The State of The State

Daniel O’Keefe, Commissioner, Department of Economic and Community Development
Chief Innovation Officer, State of CT

8:55–9:30 AM

PANEL
Academic and Industry Collaboration in Oncology Clinical Translation

Ian Krop, Chief Clinical Research Officer, Yale Cancer Center

Patricia LoRusso, Director, Early Phase Clinical Trials Program, Yale Cancer Center

William Oh, Director, Precision Medicine, Yale Cancer Center

Ahmed Sawas, Medical Director, Hematology Real-World Evidence Lead, Flatiron Health

Shashi Shankar, Chief Executive Officer, Novellia

Moderator: Jane Healy, Vice President, Therapeutic Area Head, Early Stage Oncology, Global Clinical Development, Merck Research Laboratories

9:30–10:00 AM

FIRESIDE CHAT
AI Innovation and the Role of Peer-Reviewed Publications

Raja-Elie Abdulnour, Chief Clinical Innovation Officer and Editor of NEJM Clinician, NEJM Group

Harlan Krumholz, Harold H. Hines Jr. Professor of Medicine (Cardiology), Director of Yale Center for Outcomes Research and Evaluation, Editor-in-Chief, Journal of the American College of Cardiology

Moderator: Sanjay Aneja, Associate Professor, Therapeutic Radiology; Director of Informatics and Data Science, Yale Cancer Center; Associate Editor JNCI-CS

10:00–10:30 AM

FIRESIDE CHAT
Has the Field of Cell Plasticity and Cancer Stem Cell Biology Come of Age as a Therapeutic Target?

Christine Chaffer, Founder and Chief Executive Officer, Kembi Therapeutics; Lab Head, Garvan Institute

Bob Weinberg, Founding Member, Whitehead Institute (virtually)

Moderator: Janie Merkel, Corporate Strategy Officer for Health & Life Sciences, Yale Ventures

10:30–11:05 AM

PANEL
Cracking the Code on Drugging Oncology’s Toughest Targets and Transforming Patient Outcomes

Jan Smith, Chief Scientific Officer, Revolution Medicines

Angela Cacace, Chief Scientific Officer, Arvinas

Jonathan Hurov, Executive Vice President, Discovery Biology, Parabilis Medicines

Bob Weinberg, Founding Member, Whitehead Institute (virtually)

Moderator: Danette Daniels, Vice President, Protein Degrader Platform, Foghorn Therapeutics

11:05–11:35 AM

BREAK

11:35 AM–12:10 PM

PANEL
Policy and Access in Oncology: Overcoming Barriers to Treatment

Victoria Barghout, Chief Executive Officer and Founder, Viver Health

Margaret Callahan, Chief, Division of Hematology and Oncology, The University of Connecticut School of Medicine

Dawn Holcombe, Executive Director, Connecticut Oncology Association

Padmanabhan Premkumar, President, Hartford Healthcare Medical Group

Eric Winer, Director, Yale Cancer Center; President and Physician-in-Chief, Smilow Cancer Hospital

Moderator: Jodie Gillon, President & Chief Executive Officer, BioCT

12:10–12:30 PM

MINI-KEYNOTE
From COVID Vaccines to Tumor Vaccines: Reflections and Opportunities for Breakthrough Innovation

Tal Zaks, Partner, OrbiMed Advisors LLC; Former Chief Medical Officer, Moderna

12:30–1:05 PM

PANEL
Immuno-Oncology, ADCs, Cell Therapies: The Big Picture and Emerging Modalities

Mika Derynck, Senior Vice President, Therapeutic Area Head of Oncology, Gilead

Jay Fine, President of R&D, EvolveImmune Therapeutics

Andy Souers, Vice President & Distinguished Research Fellow, Oncology Discovery Research, AbbVie

Moderator: Daniel Petrylak, Professor of Medicine and Urology, Yale School of Medicine; Director, Genitourinary Oncology Research Program, Yale Cancer Center

1:05–2:05 PM

Lunch and Networking

2:05–2:25 PM

MINI-KEYNOTE
Data Science and Tools in MedTech Innovation

Peter Schulam, Chief Scientific Officer, Johnson & Johnson MedTech

2:25–3:00 PM

PANEL
Platform Technologies and Therapeutics Innovation

Iya Khalil, Vice President & Head of Data, AI & Genome Sciences, Merck Research Laboratories

Matthew Hewitt, Vice President, CTO Manufacturing and Operations, Charles River Laboratories

Robert Abel, Executive Vice President, Chief Scientific Officer, Platform, Schrödinger

Molly He, Chief Executive Officer and Co-Founder, Element Biosciences

Moderator: David Weinstock, Venture Partner, RA Capital, Former Senior Vice President and Global Head of Oncology, Pharma R&D, Roche; Former Vice President of Discovery Oncology, Merck

3:00–3:35 PM

PANEL
Investing for Innovation in Oncology

Gwen Cheni, Director of AI/Q Fund, Connecticut Innovations

Avi Kometz, Partner, Medical Technologies, Deerfield

Maha Radhakrishnan, Sofinnova Ventures

David Reshef, Venture Partner, GV (Google Ventures)

Steve Squinto, Chief Investment Officer, JP Morgan Life Sciences Partners

Moderator: David Scheer, President, Scheer & Company

3:35–4:10 PM

PANEL
Corporate Collaborations, Strategic Partnerships, and M&A as Drivers of Innovation

Scott DeWire, Corporate Senior Vice President, Global Head of BD&L, Boehringer Ingelheim

Michael Diem, Senior Managing Partner, Pfizer Ventures; Vice President, WW Business Development, Pfizer

Rodolphe Grépinet, Senior Vice President, Corporate Development, AstraZeneca

Moderator: Michael Lefferts, Managing Director, Healthcare, Lazard

4:10–4:25 PM

Closing Reflections

David Scheer, President, Scheer & Company

Eric Winer, Director, Yale Cancer Center; President and Physician-in-Chief, Smilow Cancer Hospital

Josh Geballe, Managing Director, Yale Ventures

Jodie Gillon, President and Chief Executive Officer, BioCT

4:30–6:30 PM

YOU’RE INVITED: SPECIAL EVENT
Pizza for Proximity

Sponsored by Arvinas and Women in TPD & Induced Proximity

Pizza & networking at Bar, 254 Crown St., New Haven